Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-009 Vaccine in Solid Tumors
NCT03633110Phase 2Completed
- Sponsor
- Genocea Biosciences
- Start
- Aug 2018
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GEN-009 in cutaneous melanoma (CM), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), urothelial carcinoma (UC), renal cell carcinoma (RCC), sponsored by Genocea Biosciences. Started Aug 2018; status: completed.
02
Drugs
GEN-009
03
Conditions
cutaneous melanoma (CM)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)urothelial carcinoma (UC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03633110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633110.